Benedetti E, Pirenne J, Troppmann C, Hakim N, Moon C, Gruessner R W, Sharp H, Matas A J, Payne W D, Najarian J S
Department of Surgery, University of Illinois at Chicago, College of Medicine 60612, USA.
Transpl Int. 1996;9(5):486-91. doi: 10.1007/BF00336827.
Patients with end-stage renal and hepatic failure may be treated with combined liver and kidney transplantation (CLKTx). We reviewed the indications and outcomes of 16 CLKTx performed at the University of Minnesota between 1980 and 1994. The majority of the recipients (87.5%) were young patients affected by congenital hepatic anomalies and concomitant end-stage renal failure. Fourteen were treated with cyclosporin-based immunosuppression and had an excellent outcome: with an average of 6 years of follow-up, patient survival was 85.7%, liver graft survival 85.7%, and kidney graft survival 72%. The incidence of rejection episodes was similar to the rate of rejection in our solitary kidney and liver transplants. In conclusion, our experience supports the value of CLKTx in treating patients with simultaneous failure of both organs or with congenital enzymatic hepatic deficits leading to renal failure.
终末期肾衰和肝衰患者可接受肝肾联合移植（CLKTx）治疗。我们回顾了1980年至1994年间在明尼苏达大学进行的16例CLKTx的适应证和治疗结果。大多数受者（87.5%）为患有先天性肝脏异常并伴有终末期肾衰的年轻患者。14例患者接受了以环孢素为基础的免疫抑制治疗，效果良好：平均随访6年，患者生存率为85.7%，肝移植生存率为85.7%，肾移植生存率为72%。排斥反应的发生率与我们单独进行肾移植和肝移植时的排斥率相似。总之，我们的经验支持CLKTx在治疗同时出现两个器官功能衰竭或因先天性肝脏酶缺乏导致肾衰患者中的价值。
